Compared with treatment methods used in the DCCT 20-30 years ago, rapidand long-acting insulin analogs, improved insulin pumps and blood glucose meters, continuous glucose monitoring (CGM) devices, and integrated sensor-augmented insulin pump systems with automatic threshold suspend capabilities have provided clinicians and patients with new tools to achieve target HbA 1c levels more readily and safely (5) . Whether and to what extent these advances in diabetes technology have been translated into better glycemic control in patients with type 1 diabetes in the U.S. has not been established due, in part, to the lack of a broadbased, large-scale, multisite registry that covered patients at all ages across the life span. Supported by a grant by the Helmsley Charitable Trust, the T1D Exchange Clinic Network was established to fill this gap. Leading adult and pediatric diabetes treatment centers with a wide geographical distribution throughout the U.S. (Supplementary Fig. 1 ) are participating in the T1D Exchange Clinic Network, with the Jaeb Center for Health Research in Tampa, FL serving as the coordinating center. The first initiative of the T1D Exchange Clinic Network was the establishment of the T1D Exchange clinic registry.
Initially, 25,833 participants who ranged in age from 2 to 95 years were enrolled into the registry between September 2010 and August 2012. A comprehensive set of baseline clinical, laboratory, and demographic data were obtained for each participant at registry enrollment and the core data have been updated annually. The data collected at baseline have provided a number of particularly notable findings (Supplementary Table 1) , including showing that most adults and children with type 1 diabetes were not achieving HbA 1c goals set by the ADA and ISPAD (6) (7) (8) ; that there was a relationship between increased frequency of blood glucose testing and lower HbA 1c levels (9) ; that ethnic/racial and socioeconomic factors played a role in differences in metabolic control and use of insulin pumps in youth with type 1 diabetes (10); that diabetic ketoacidosis (DKA) occurred less frequently in insulin pump users than injection users (11, 12) ; and that CGM was being used by only a small proportion of adults and children with type 1 diabetes (13) .
In this article we report the results of the most recent follow-up data for registry participantsddata that have allowed us to prospectively assess trends in outcomes over time. We examine the current state of metabolic control and use of advanced diabetes technologies and whether cross-sectional changes have occurred over time, as well as assess the current frequencies of SH and DKA by participant self-report.
METHODS
The T1D Exchange Clinic Network currently includes 76 U.S.-based pediatric and adult endocrinology practices in 33 states. Seventeen of the centers primarily care for adult patients, 38 primarily care for pediatric patients, and 21 care for both; 58 are institution based, 17 are community based, and 1 is in a managed care setting. During the initial registry enrollment period, 25,833 individuals with type 1 diabetes (14,593 ,18 years old and 11,240 $18 years old) were enrolled. Details on the eligibility criteria, informed consent process, and baseline data collection have been reported previously (14) . Core enrollment data are updated annually from medical records of all participants who had at least one clinic visit in the prior year. New modules concerning issues not addressed at enrollment have been designed for subsets of participants during annual updates.
This report includes data from 16,061 participants for whom an annual update was completed between 1 September 2013 and 1 December 2014 who had an available HbA 1c value associated with the office visit used for the medical record update. Participants with a history of pancreas or islet cell transplantation and those pregnant at the time of the most recent annual update were excluded. This report also includes the responses to a detailed questionnaire directed at specific aspects of diabetes management completed by a subset of 2,561 participants who chose to complete an electronic questionnaire during 2013. For the 16,061 with an annual update, clinical characteristics and diabetes management at the time of the most recent annual update were tabulated according to age-group. Use of an insulin pump and CGM were obtained from clinic medical records, and the frequency of selfmonitoring of blood glucose (SMBG) was from the meter download at the clinic visit (available for 10,555 [66%] participants). Due to the variability and incompleteness of medical record recording of SH and DKA, the occurrence of these events during the prior 3 months was based on self-report data obtained from the subset of participants/caregivers who completed the web-based questionnaire. SH was defined as a participantreported event that resulted in loss of consciousness or seizure. DKA was defined as participant-reported DKA diagnosed by a doctor that required treatment in a health care facility. Cross-sectional comparisons of data collected at enrollment were compared with the most recent update data for the 13,848 of the 16,061 participants who already had diabetes for at least 1 year at the time of initial registry enrollment. Cross-sectional comparisons of the occurrences of DKA and SH at enrollment versus recent update were not performed due to differences in the way in which events were collected between the two time points. In order to assess HbA 1c over the life span, participants were grouped by year of age at the time of the most recent HbA 1c value available (87% measured with an in-clinic point of care device, 11% local laboratory, and 2% unknown), and a mean HbA 1c was computed for that age using data from each of the 16,061 participants with a recent update. All statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
At the time of the most recent update, the 16,061 participants ranged in age from 2.7 to 93.9 years old, duration of type 1 diabetes ranged from 1.5 to 83.1 years, and 50% were female and 83% non-Hispanic white. Socioeconomic factors and clinical and diabetes management characteristics of the cohort stratified by age-group are shown in Table 1 . Among participants with diabetes duration of $1 year at the time of registry enrollment, those with a recent update had a slightly lower HbA 1c at enrollment compared with those who did not have an update, particularly in participants .13 years of age (Supplementary Table 2 ).
Metabolic Control
Compared with the overall average HbA 1c of 8.2 61.4% (66 6 15.3 mmol/mol) at enrollment, the average HbA 1c was 8.4 61.6% (68 6 17.5 mmol/mol) at the most recent update, with the worsening over time largely being limited to the 13-25-year-olds (Table 2) . (5) 16 (7) 164 (5) 292 (6) 124 (4) 89 (3) 55 (3) Hispanic or Latino 1,294 (8) 25 (11) 336 (10) 540 (11) 263 (9) 106 (4) 24 (1) Other 699 (4) 16 (7) 194 (6) 255 (5) 121 (4) 81 (3) 32 (2 17 (,1) ‡Income data missing for 4,106 participants, education data missing for 2,271 participants, and insurance data missing for 1,432 participants. Education level is the parents' highest education level for participants ,18 years of age and is the participants' education level for participants .18 years of age. *Underweight/normal weight defined as ,85th BMI percentile adjusted for age and sex for participants ,20 years of age and BMI ,25 for adults $20 years of age. Overweight defined as 85th to ,95th BMI percentile for participants ,20 years of age and BMI 25 to ,30 for adults $20 years of age. Obese defined as $95th BMI percentile for participants ,20 years of age and BMI $30 for adults $20 years of age. #SMBG from meter download was available for 10,555 participants. §Only available for a subset of participants who completed an electronic questionnaire asking about insulin and device use; n = 2,561 (n = 47 for 2-5 years, 534 for 6-12 years, 455 for 13-17 years, 451 for 18-25 years, 661 for 26-49 years, and 413 for $50 years). |Includes thiazolidinediones and sulfonylureas.
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As previously reported, across all agegroups, HbA 1c was highest among nonHispanic black participants, participants with lower annual household income, and those who performed SMBG less than four times per day (Table 3) . On average, participants using an insulin pump or continuous glucose monitor tended to have lower HbA 1c values (Table 3) .
Utilization of Diabetes Technologies, Insulin, and Other Glucose-Lowering Agents
An insulin pump was being used by 60% of participants, ranging from a low of 55% in 18-25-year-olds to 65% in 6-12-year-olds. In a cross-sectional comparison of enrollment with most recent update, the greatest relative increase in pump use was in pediatric participants likely due to an increase in mean diabetes duration, whereas pump use did not change in 18-25-yearolds and increased only slightly in older participants (Tables 1 and 2) .
Across all age-groups, the use of CGM was more frequent at most recent update compared with enrollment and the frequency of SMBG by meter download did not change from enrollment; on both occasions, the frequency of SMBG was highest but CGM use was lowest in pediatric patients. Nearly two-thirds of patients/families reported never downloading SMBG data.
Insulin aspart was being used in pumps slightly more frequently than insulin lispro (Supplementary Table 3 ). Among injection users, lispro was the most common rapid-acting insulin being used and glargine the most common long-acting insulin (Supplementary Table 3 ). Use of glucoselowering agents as adjuncts to insulin treatment of type 1 diabetes was uncommon across all age-groups. Metformin was the most common noninsulin glucoselowering drug being used but only by 6% of those $26 years of age. No other noninsulin drug was being used by .2% of those $26 years of age or by .1% of younger participants.
SH and DKA
Among the subset of 2,561 participants who completed the participant questionnaire, 6% reported having had a seizure or loss of consciousness due to hypoglycemia in the prior 3 months, with the highest occurrence being among those who were 50 years old or older. An increase in frequency of SH with increasing age and duration of diabetes was also observed on enrollment (12) . Insulin pump use was associated with a lower frequency of SH. Participants across all age-groups who There are less participants in the younger age-groups for the current update data due to aging over time and they are included in the older agegroups. #Available for 5,787 participants with a meter download in the medical record at enrollment and most recent clinic visit. §Available for 2,124 participants who completed the participant questionnaire and did not respond "Don't know." 2015 achieved lower HbA 1c levels did so without increased frequency of SH (Table 4) . At least one DKA event in the prior 3 months was reported by 3% of the 2,561 participants, with the highest occurrence being young adults (5%). With the exception of the 2-5-year-old agegroup where the sample size was small, the frequency of DKA tended to be higher among participants with higher HbA 1c levels and slightly lower among participants using an insulin pump.
CONCLUSIONS
The HbA 1c data collected by the T1D Exchange clinic registry at a large, geographically diverse number of pediatric and adult diabetes treatment centers provide an up-to-date picture of metabolic control of type 1 diabetes across the life span. A positive aspect of these data is that the mean HbA 1c levels in patients $30 years of age are lower than the ;8.0% (;64 mmol/mol) that has been observed in DCCT/EDIC patients during the past 20 years (1). The most troubling aspect of the data is that the mean HbA 1c level of 9.0% (75 mmol/mol) in 13-17-year-olds in the registry is only slightly lower than the 9.5% (80 mmol/mol) seen in 13-17-year-olds at the start of the DCCT in the 1980s (15). Clearly, advances in diabetes management over the past two decades have been less successful in overcoming the special challenges in managing teenagers than adults with type 1 diabetes. Our data also indicate that the majority of "emerging adults" in their 20s do not fully emerge with regard to glycemic control until they reach 30 years of age. Given DCCT/ EDIC data on the persistent benefit of intensive versus conventional glucose control (7.3 vs. 9.1% [56 vs. 76 mmol/mol] during the DCCT) on vascular outcomes 20 years later (16), the contemporary elevated HbA 1c seen in the adolescents and young adults in the T1D Exchange suggests a similarly elevated risk for future complications until they reach 30 years of age.
In a cross-sectional comparison, the average HbA 1c at the most recent update was higher than at enrollment (8.4 vs. The observation that many patients in the registry were able to achieve target HbA 1c levels without the exponential increase in the frequency of SH seen in the DCCT is a very positive finding (6,7). Similar decreases in HbA 1c levels without concomitant increases in SH have been observed in clinical trials of new insulin analogs (18), with use of new insulin pumps (19) , and in CGM trials (20) . Our data also indicate that DKA remains a problem in a substantial percentage of patients (11, 12) . Since the risk of DKA was increased in participants with HbA 1c levels .9.0% (75 mmol/mol), poor compliance with their diabetes treatment regimens undoubtedly contributes to the increased risk of DKA. Conversely, greater compliance with the daily tasks of managing diabetes may help explain the lower frequency of DKA that we observed in pump versus injection patients. The data provide no indication of a higher DKA rate in pump users, a theoretical concern due to the potential for infusion set failure.
Despite elevations in HbA 1c levels in every age-group of participants with type 1 diabetes, only ;5% were being treated with an adjunctive glucose-lowering agent, mostly metformin. Treatment with metformin has been associated with only a modest lowering of HbA 1c in adults with type 1 diabetes (21), whereas no change in metabolic control was seen in a recent large-scale clinical trial in overweight adolescents (22) . These observations underscore the continuing need for the testing of new classes of glucose-lowering agents that have been approved for treatment of type 2 diabetes in patients with type 1 diabetes. Since adolescents with type 1 diabetes are at greatest need for new treatment options, pivotal trials for approval of these drugs in type 1 diabetes in adolescents should not be delayed until completion of adult studies.
A limitation in interpreting these results is that all subjects in the T1D Exchange clinic registry are treated at centers that focus on the care of type 1 diabetes. Thus, uninsured individuals likely are underrepresented in the cohort and pump use may Even if certain biases are present, it is highly unlikely that the T1D Exchange data demonstrating that only a minority of children and adults with type 1 diabetes achieve HbA 1c targets is an underestimate. The high proportions of individuals not achieving glycemic targets with current therapies highlighted in our analyses make development and dissemination of an artificial pancreas or safe and effective islet replacement imperative.
